Are GlaxoSmithKline plc, SSE plc And Admiral Group plc The Best Income Stocks In The World?

Should you rush out to buy these 3 high-yielders? GlaxoSmithKline plc (LON: GSK), SSE PLC (LON: SSE) and Admiral Group plc (LON: ADM).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

A year ago, it seemed likely that interest rates would have risen by at least 0.25% from their historic low. The UK economy was performing relatively well and while a General Election was on the horizon, it seemed as though ‘life support’ (i.e. a rock-bottom interest rate) was no longer necessary.

Today it looks like high-yielding stocks could remain in vogue for at least another year. Why?

The economy has performed relatively well in the last year but interest rates are no higher. Income-seeking investors continue to struggle since their cash balances are providing a relatively poor return. And while zero inflation means a real return on offer even from cash, a gross yield of around 2% is still very disappointing.

Looking ahead, interest rates could realistically remain at or near their lows over the next year simply because inflation is showing little sign of rising. 

Powerful pipeline

With a yield of 6%, GlaxoSmithKline (LSE: GSK) certainly has headline income appeal. It remains one of the highest yielding stocks in the FTSE 100 and although dividends per share are due to be frozen over the next couple of years, rapid dividend growth beyond that is very much on the horizon.

What’s behind that expected growth? GlaxoSmithKline’s drug pipeline is among the most diverse and appealing within the global pharmaceutical industry. It has multiple potential HIV treatments within its ViiV Healthcare division and with the company aiming to reduce costs by over £1bn in the coming years, it appears to have the right mix of sales growth potential as well as the scope to boost margins.

This is a key reason why GlaxoSmithKline is expected to increase its bottom line by 11% next year, which indicates that as well as being a strong income play, it also offers significant near-term growth potential.

Rising incomes

Similarly, SSE (LSE: SSE) also has a very desirable yield of 6.2% and unlike GlaxoSmithKline, its dividends are forecast to rise next year. The increase is expected to be just 1.6%, but that’s still ahead of inflation and so represents a real-term rise in shareholders’ incomes.

SSE also seems well-placed to at least match inflation when it comes to increases in shareholder payouts over the long term. Its dividends are currently covered 1.3 times by profit, which is relatively healthy. And its shares offer upside potential via a relatively appealing valuation. For example, SSE trades on a price to earnings (P/E) ratio of 12.7 indicating that it could deliver an excellent total return next year.

Steady as she goes

Meanwhile insurance business Admiral (LSE: ADM) currently yields 5.9% and while an increase to insurance premium tax has the potential to squeeze profitability within the car insurance sector, it appears to be well-positioned to overcome any such short term problems. The reason? The wide range of brands Admiral owns. They provide the company with a commanding position within the car insurance industry, allowing it to maintain relatively high levels of profitability.

As well as being a high-yielding stock, Admiral also offers a degree of consistency. For example, earnings increased in four of the last five years and with it having a beta of 0.86, it should offer a less volatile shareholder experience than many of its index peers in 2016.

Peter Stephens owns shares of Admiral Group, GlaxoSmithKline, and SSE. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Could this cheap FTSE 100 stock be the next Rolls-Royce?

Paul Summers casts his eye over a battered-but-high-quality FTSE 100 stock. Is this the next top-tier company to stage a…

Read more »

ISA Individual Savings Account
Investing Articles

Hesitant over a Stocks and Shares ISA? Here’s a way to deal with scary markets

Volatile stock markets are scaring potential investors away from getting started with their first Stocks and Shares ISA in 2026.

Read more »

This way, That way, The other way - pointing in different directions
Market Movers

Standard Life’s announced a £2bn deal but its share price is largely unchanged. Why?

James Beard considers why the Standard Life share price didn’t take off today (15 April) after the group announced it…

Read more »

Happy parents playing with little kids riding in box
Investing Articles

Up 12% in a month, Hollywood Bowl is a UK dividend stock on a roll

This 5%-yielding dividend stock was one of the top performers in the FTSE 250 index today. What sent it flying…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

Young investors are taking the stock market on a rollercoaster ride. Here’s how retirees can buckle up

Mark Hartley reveals the volatile impact that younger investors are having on the stock market and how UK retirees can…

Read more »

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

£7,500 invested in Aviva shares 5 years ago is now worth…

A lump sum pumped into Aviva shares half a decade ago has grown a lot. Andrew Mackie looks at the…

Read more »

Young female hand showing five fingers.
Investing Articles

Could £20,000 invested in these 5 dividend shares produce £14,760 of passive income over the next 10 years?

James Beard considers the potential of dividend shares to deliver amazing levels of passive income. Here are five that have…

Read more »

Workers at Whiting refinery, US
Investing Articles

At 570p, is it too late to consider buying BP shares?

Since the end of February, when the conflict in the Middle East started, BP shares have soared nearly 20%. But…

Read more »